Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

30.77
Delayed Data
As of 4:15pm ET
 +0.17 / +0.56%
Today’s Change
28.82
Today|||52-Week Range
46.24
-28.71%
Year-to-Date
Myriad Genetics myChoice Cancer Test Findings Encourage
10:07am / Zacks.com - Paid Partner Content
Shares of Tesaro, Inc. Have More Than Doubled Today. Here's Why
Jun 29 / MotleyFool.com - Paid Partner Content
Myriad Genetics: Study Data Drives Growth, Competition Rife
9:39am / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close30.60
Today’s open30.77
Day’s range30.52 - 31.00
Volume1,206,750
Average volume (3 months)909,408
Market cap$2.2B
Dividend yield--
Data as of 4:15pm ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)-52.00%
Earnings growth (this year)--
Earnings growth (next 5 years)+14.05%
Revenue growth (last year)-7.08%
P/E ratio20.8
Price/Sales3.50
Price/Book3.18

Competitors

 Today’s
change
Today’s
% change
GLPGGalapagos NV-0.61-1.10%
IPXLImpax Laboratories I...+0.48+1.67%
GWPHGW Pharmaceuticals P...+2.21+2.41%
MDCOMedicines Co+0.49+1.46%
Data as of 4:00pm ET, 07/01/2016

Financials

Next reporting date--
EPS forecast (this quarter)--
Annual revenue (last year)$723.1M
Annual profit (last year)$80.2M
Net profit margin11.09%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts

Partner Offers

Search for Jobs